Видео ютуба по тегу Os Analysis

Первичный анализ ОС фазы III STELLAR-303: zanza + atezo против rego при ранее леченном мКРР
Первичный анализ ОС фазы III STELLAR-303: zanza + atezo против rego при ранее леченном мКРР
Final OS analysis of sacituzumab govitecan in TROPiCS-02
Final OS analysis of sacituzumab govitecan in TROPiCS-02
IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC
IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC
CA Log AnalyzerTM for DB2 for z/OS - Quiet Point Analysis
CA Log AnalyzerTM for DB2 for z/OS - Quiet Point Analysis
Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study
Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study
Jason Westin, MD, on the Phase III ZUMA-7 Primary OS Analysis
Jason Westin, MD, on the Phase III ZUMA-7 Primary OS Analysis
Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphoma
Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphoma
GC 503 - Multikernel: A detailed Analysis of Multicore OS Kernel
GC 503 - Multikernel: A detailed Analysis of Multicore OS Kernel
OS AOL Video Project Virtual Machine Analysis + Tutorial
OS AOL Video Project Virtual Machine Analysis + Tutorial
Course Trailer - OS Analysis with osquery
Course Trailer - OS Analysis with osquery
TILs and OS in HER2+ early breast cancer: 10-year updated analysis of the ShortHER trial
TILs and OS in HER2+ early breast cancer: 10-year updated analysis of the ShortHER trial
JAKARTA and JAKARTA2: OS and PFS analysis of fedratinib in myelofibrosis
JAKARTA and JAKARTA2: OS and PFS analysis of fedratinib in myelofibrosis
Final OS analysis from ARCHES
Final OS analysis from ARCHES
Performance Analysis Using OS Watcher
Performance Analysis Using OS Watcher
SECOMBIT: 4-year OS and tPFS data and preliminary biomarker analysis
SECOMBIT: 4-year OS and tPFS data and preliminary biomarker analysis
ICARIA-MM: final OS analysis
ICARIA-MM: final OS analysis
Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
IOU YouTube: How are OS & PFS assessed in Immuno-Oncology research?
IOU YouTube: How are OS & PFS assessed in Immuno-Oncology research?
OS Therapies (OSTX|$57.9M) - 2025 Q2 Earnings Analysis
OS Therapies (OSTX|$57.9M) - 2025 Q2 Earnings Analysis
OS Overview and Analysis
OS Overview and Analysis
Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6
Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6
[MacG] OS X Syntax Analysis
[MacG] OS X Syntax Analysis
ARCHES: 5-year OS analysis of enzalutamide plus ADT in mHSPC
ARCHES: 5-year OS analysis of enzalutamide plus ADT in mHSPC
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?